Can tumor angiogenesis be inhibited without resistance?

[1]  S. Rafii,et al.  Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.

[2]  D. Ray,et al.  Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. , 2003, Cancer research.

[3]  R. Kerbel,et al.  A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. , 2002, Differentiation; research in biological diversity.

[4]  K. Maiese,et al.  Angiogenesis and plasticity: role of erythropoietin in vascular systems. , 2002, Journal of hematotherapy & stem cell research.

[5]  T. Habuchi,et al.  Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. , 2002, The Tohoku journal of experimental medicine.

[6]  E. Kleinerman,et al.  Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  W. Gradishar,et al.  A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Hayward,et al.  Altered Patterns of Cellular Gene Expression in Dermal Microvascular Endothelial Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus , 2002, Journal of Virology.

[9]  R. Kerbel,et al.  A role for survivin in chemoresistance of endothelial cells mediated by VEGF , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Rafii,et al.  Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.

[11]  A. Nicholson,et al.  Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas , 2002, British Journal of Cancer.

[12]  B. Barlogie,et al.  Thalidomide in the management of multiple myeloma. , 2001, Seminars in hematology.

[13]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[14]  R. Jain,et al.  Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation , 2001, Circulation research.

[15]  Lei Xu,et al.  Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.

[16]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[17]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[18]  F. Peale,et al.  Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.

[19]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[20]  B. Barlogie,et al.  Thalidomide in the management of multiple myeloma. , 2001, Seminars in oncology.

[21]  D. Hicklin,et al.  Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.

[22]  R. B. Campbell,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[23]  Paul S. Meltzer,et al.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  O. Volpert,et al.  In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. , 2001, Genes & development.

[25]  J. Bolz,et al.  Semaphorin 3A–Vascular Endothelial Growth Factor-165 Balance Mediates Migration and Apoptosis of Neural Progenitor Cells by the Recruitment of Shared Receptor , 2001, The Journal of Neuroscience.

[26]  S. Rafii,et al.  Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[27]  M. Gassmann,et al.  Induction of HIF–1α in response to hypoxia is instantaneous , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  G. Fontanini,et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  A. Harris,et al.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway , 2001, British Journal of Cancer.

[30]  M. Hendrix,et al.  Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). , 2001, Cancer research.

[31]  G. Sledge,et al.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. , 2001, Cancer research.

[32]  L. Ellis,et al.  Endothelial cell apoptosis is inhibited by a soluble factor secreted by human colon cancer cells , 2001, International journal of cancer.

[33]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[34]  M. Hendrix,et al.  Molecular determinants of ovarian cancer plasticity. , 2001, The American journal of pathology.

[35]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Kanomata,et al.  Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. , 2001, Cancer research.

[37]  I. Zachary,et al.  Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. , 2001, Cardiovascular research.

[38]  G. Sledge,et al.  Redefining the target: chemotherapeutics as antiangiogenics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Nolan,et al.  Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  W. Middlesworth,et al.  All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. , 2001, Journal of pediatric surgery.

[41]  A. Andres,et al.  Vascular remodelling during the normal and malignant life cycle of the mammary gland , 2001, Microscopy research and technique.

[42]  S. Soker,et al.  Neuropilin‐1 expression by tumor cells promotes tumor angiogenesis and progression , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  R. Kerbel,et al.  Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.

[44]  D. O’Rourke,et al.  Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. , 2000, Cancer research.

[45]  Wenbiao Liu,et al.  Endothelial cell survival and apoptosis in the tumor vasculature , 2000, Apoptosis.

[46]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[47]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[48]  M. Hendrix,et al.  Molecular biology of breast cancer metastasis Molecular expression of vascular markers by aggressive breast cancer cells , 2000, Breast Cancer Research.

[49]  S. Mader,et al.  Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis , 2000, Oncogene.

[50]  A Sasaki,et al.  Negative regulation of cytokine signaling pathways. , 2000, Annual review of immunology.

[51]  G. Neufeld,et al.  Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of Placenta Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF* , 2000, The Journal of Biological Chemistry.

[52]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[53]  R. D'Amato,et al.  Genetic heterogeneity of angiogenesis in mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[55]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[56]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[57]  K. Hörmann,et al.  Expression of basic fibroblast growth factor protein and its down‐regulation by interferons in head and neck cancer , 2000, Head & neck.

[58]  A. Pozzi,et al.  Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[60]  K. Kinzler,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[61]  R. Kerbel,et al.  Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.

[62]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[63]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  C. Compton,et al.  Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1 , 1999, Nature Medicine.

[65]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[66]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[67]  A. Adamis,et al.  Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. , 1999, Investigative ophthalmology & visual science.

[68]  Wei Li,et al.  VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. , 1999, Experimental cell research.

[69]  E. Sham,et al.  The lifetime of hypoxic human tumor cells. , 1998, International journal of radiation oncology, biology, physics.

[70]  J. Wijnholds,et al.  Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage , 1998, The Journal of experimental medicine.

[71]  J. Raleigh,et al.  Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.

[72]  R. Bergmann,et al.  Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.

[73]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[74]  T. Mayumi,et al.  Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors. , 1998, Anticancer research.

[75]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[76]  V. Dixit,et al.  Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[77]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[78]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[79]  A. Karsan,et al.  Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. , 1997, The American journal of pathology.

[80]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[81]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[82]  B. Wüthrich.  AN INTERNATIONAL SYMPOSIUM , 1997 .

[83]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[84]  Y. Kakeji,et al.  Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[85]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[86]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[87]  Y. Rustum,et al.  MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. , 1996, The American journal of pathology.

[88]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[89]  R. Dickson,et al.  The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[91]  M. Barrand,et al.  Comparisons of P‐glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta , 1995, FEBS letters.

[92]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[93]  H. Shimada,et al.  Cancer seed and soil can be highly selective: human-patient colon tumor lung metastasis grows in nude mouse lung but not colon or subcutis. , 1995, Anticancer research.

[94]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[95]  B. Teicher,et al.  Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo. , 1994, Cancer letters.

[96]  J. Folkman,et al.  The combination of antiagniogenic agents to inhibit primary tumor growth and metastasis , 1993 .

[97]  B. Teicher,et al.  Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.

[98]  I. Fidler,et al.  Orthotopic implantation is essential for the selection, growth and metastasis of human real cell cancer in nude mice , 1990, Cancer and Metastasis Reviews.

[99]  P. Brousset,et al.  Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. , 1990, British Journal of Cancer.

[100]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[101]  G. Poste,et al.  Stephen Paget, M.D., F.R.C.S., (1855–1926) A retrospective , 1989, Cancer and Metastasis Reviews.

[102]  Agnes W. O'Brien.  Seed and Soil , 1905, The Elementary School Teacher.

[103]  Fay M. Hansen,et al.  Strain differences and inheritance of angiogenic versus angiostatic activity in oestrogen-induced rat pituitary tumours , 2004, Angiogenesis.

[104]  Barbara Krammer,et al.  bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer , 2004, Clinical & Experimental Metastasis.

[105]  L. Ellis,et al.  Role of the Tumor Microenvironment in Mediating Response to Anti-angiogenic Therapy , 2004, Cancer and Metastasis Reviews.

[106]  R. Kerbel,et al.  Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.

[107]  P. Lambin,et al.  Modulation of cell death in the tumor microenvironment. , 2003, Seminars in radiation oncology.

[108]  J. Lewin,et al.  A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer , 2001 .

[109]  G. Neufeld,et al.  NEUROPILIN-2 AND NEUROPILIN-1 ARE RECEPTORS FOR VEGF165 AND PLGF-2, BUT ONLY NEUROPILIN-2 FUNCTIONS AS A RECEPTOR FOR VEGF145 . , 2000 .

[110]  R. Swerlick,et al.  Differential regulation of vascular cell adhesion molecule-1 gene transcription by tumor necrosis factor alpha and interleukin-1 alpha in dermal microvascular endothelial cells. , 1996, Blood.

[111]  R. Durand,et al.  Contribution of transient blood flow to tumour hypoxia in mice. , 1995, Acta oncologica.

[112]  E. Viadana,et al.  Patterns of metastases in adenocarcinomas of man. An autopsy study of 4,728 cases. , 1975, Journal of medicine.